Current status of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccine development: memorandum from a joint WHO/NIAID meeting

Bull World Health Organ. 1997;75(4):307-13.

Abstract

A Joint WHO/National Institute of Allergy and Infectious Diseases (NIAID) meeting on the current status of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccine development was held in Bethesda, MD, from 30 September to 1 October 1996. The meeting summarized the worldwide impact of RSV and PIV3; presented the current status of development of RSV and PIV3 vaccines; and examined the applications of recombinant DNA technology to the development and characterization of vaccines and to the understanding of viral pathogenesis.

MeSH terms

  • Adult
  • DNA, Complementary / genetics
  • DNA, Recombinant
  • DNA, Viral / genetics
  • Humans
  • Infant
  • Infant, Newborn
  • Mutation
  • National Institutes of Health (U.S.)
  • Parainfluenza Virus 3, Human / genetics
  • Parainfluenza Virus 3, Human / immunology*
  • Respiratory Syncytial Viruses / genetics
  • Respiratory Syncytial Viruses / immunology*
  • Respirovirus / immunology
  • United States
  • Vaccines, Attenuated
  • Viral Vaccines* / genetics
  • Viral Vaccines* / immunology
  • World Health Organization

Substances

  • DNA, Complementary
  • DNA, Recombinant
  • DNA, Viral
  • Vaccines, Attenuated
  • Viral Vaccines